- Opening Hook
When your client asks for “cost savings,” and you hand them a GenAI bot that never sleeps—that’s Sagility’s vibe this quarter. While the US healthcare industry drowns in tariffs, reforms, and paperwork thicker than a Bollywood script, Sagility’s management turned it into a 25% growth story. Ramesh Gopalan & team basically said: “AI is eating our margins? Fine, we’ll eat more contracts.”
Keep reading—because when CFOs start talking in constant currency and end with “25% EBITDA,” you know the spreadsheets have gone nuclear.
- At a Glance
- Revenue ₹1,658.5 Cr – Up 25% YoY; CFO insists it’s “real” and not Excel magic.
- EBITDA ₹435.2 Cr (26.2%) – GenAI officially earns its badge as cost assassin.
- PAT ₹301 Cr – Up 84%; someone’s finally enjoying forex gains.
- H1 Revenue ₹3,197 Cr – Up 25.5%; even the rupee couldn’t dull the shine.
- Interim Dividend ₹0.05/share – Barely a samosa, but hey, it’s a start.
- Employee Count 44,185 – The “AI won’t take jobs” crowd quietly sweating.
- Management’s Key Commentary
Ramesh Gopalan: “We delivered 25% growth and 26% margins—proof that GenAI works.”
(Translation: Machines now officially outperform middle management. 😏)
Ramesh: “Payer segment grew 24%, provider 33%. Healthcare chaos = more contracts.”
(Hospitals panic, Sagility profits. Circle of life.)
Ramesh: “We’ve deployed 25 AI use cases across nine clients.”
